Sorrento Therapeutics Hits Ch. 11 With Over $100M In Debt

By Rick Archer · February 13, 2023, 11:06 AM EST

California pharmaceutical research firm Sorrento Therapeutics Inc., a developer of cancer, COVID-19 and chronic pain treatments, filed for Chapter 11 protection in a Texas bankruptcy court Monday with about $135 million...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

Sorrento Therapeutics, Inc.

Case Number

Court

Texas Southern

Nature of Suit

Date Filed

February 13, 2023

Recent Articles By Rick

October 01, 2024
Nostrum Labs Hits Ch. 11 A Year After Medicaid Settlement
June 27, 2024
Insurers Call Rite Aid Ch. 11 Opioid Deal Unfair
June 03, 2024
Judge Says It's Time For DIP Deal For Steward Healthcare
May 28, 2024
Medical Test Maker To Liquidate After FDA Slams COVID Kits
May 17, 2024
Cano Health Strikes $7M Deal With Unsecured Creditors
May 07, 2024
Steward Health Gets Ch. 11 Loan, Says It Plans Hospital Sales
May 06, 2024
Hospital Chain Steward Health Hits Ch. 11 With Over $1B Debt
May 03, 2024
Acorda Therapeutics Strikes Creditor Deal On Ch. 11 Loan
May 02, 2024
Skin Care Drug Co. Gets OK For Ch. 11 Wind-Down Plan
March 19, 2024
Skin Care Drug Co. Can Ask Creditors To OK Ch. 11 Plan